New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
News|Articles|March 26, 2024
Evidence-Based Novel Therapies for Bipolar Depression: Top 5 Takeaways
Author(s)Erin O'Brien
Expiring on May 20, 2024, this CME discusses how to apply several novel treatment approaches in the treatment of patients with bipolar depression. Here are 5 key takeaways.
Advertisement
Advertisement
Related to this article
Phase 1 driving simulation finds bedtime GlyphAllo for major depressive disorder shows no next-morning driving impairment, while advancing allopregnanolone-based oral treatment development.
Discuss depression care challenges, comorbidities, and new treatments—submit cases, research, or CME ideas for Psychiatric Times’ September 2026 series.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
The Silence Between the Questions: Reflections on Adolescent Suicide Risk When Intent Is Unclear
3
New Adult ADHD Guidelines: What Resources Are Coming Soon
4
Brenipatide for Alcohol Use Disorder: Emerging Findings
5